Intermediate Versus Low-Dose Low-Molecular-Weight Heparin in Pregnant and Postpartum Women with a History of Venous Thromboembolism (Highlow Study)

Saskia Middeldorp, M.D., Ph.D.
Radboud University Medical Center
Nijmegen, the Netherlands

Pregnancy-related venous thromboembolism (VTE) is the leading cause of maternal mortality and morbidity. The optimal dose of low-molecular-weight heparin (LMWH) to prevent recurrent VTE in pregnancy is uncertain. In this presentation, Saskia Middeldorp, M.D., Ph.D., discusses the Highlow study, a randomized controlled trial in which the efficacy and safety of intermediate versus low-dose LMWH in 1,110 women with a history of VTE has been compared. In addition to the VTE dynamics in the two randomized groups of women, the impact of this trial on guidelines and clinical practice are also discussed.

Previous Article Sirtuin 1 as an Endogenous Inhibitor of NETosis
Next Article Roles of Factor VIII in Endothelial Cell Biology More than a Coagulation Factor